首页> BMJ open> Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial.

Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial.

导出 OA

翻译打印收藏纠错

第一作者： Jean-Baptiste,Trouiller

第一单位： Department of Public Health, Aix-Marseille University, Marseille, France jean.baptiste.trouiller@pierre-fabre.com.;Pierre Fabre Laboratories, Paris, France.

作者： Jean-Baptiste,Trouiller ^[1] ; Bérengère,Macabeo ^[2] ; Andrew,Poll ^[3] ; Dan,Howard ^[4] ; Andy,Buckland ^[4] ; Marine,Sivignon ^[5] ; Emilie,Clay ^[5] ; David,Malka ^[6] ; Emmanuelle,Samalin ^[7] ; Mondher,Toumi ^[5] ; Philippe,Laramée ^[2]

作者单位： Department of Public Health, Aix-Marseille University, Marseille, France jean.baptiste.trouiller@pierre-fabre.com.;Pierre Fabre Laboratories, Paris, France. ^[1] Department of Public Health, Aix-Marseille University, Marseille, France.;Pierre Fabre Laboratories, Paris, France. ^[2] Pierre Fabre Ltd, Reading, UK. ^[3] Mtech Access, Bicester, UK. ^[4] Creativ Ceutical, Paris, France. ^[5] Medical Oncology Department, Gustave Roussy, Université Paris-Saclay, Villejuif, France. ^[6] Medical Oncology Department, Institut du Cancer de Montpellier, Montpellier, France. ^[7]

关键词 Adult oncology Gastrointestinal tumours HEALTH ECONOMICS